HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose

This article was originally published in The Tan Sheet

Executive Summary

FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court

You may also be interested in...

Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms

A 1final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids will become effective April 12, FDA announced Feb. 6

DSHEA Implementation Action Expected In Second Session Of 108th Congress

A House version of the Dietary Supplement Health & Education Act "Full Implementation" Senate bill is expected early this year, marking the impact of industry efforts to respond to a challenging year in Washington

FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review

FDA's regulatory framework for removing dangerous dietary supplements from the market under the Dietary Supplement Health & Education Act's "unreasonable risk" standard will be issued shortly by the agency

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts